In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1498-1505

  Gupta, Anukriti ^a   Le, Amy ^a   Belinka, Benjamin A ^b   Kachlany, Scott C ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^b Actinobac Biomed Inc   (United States)

Author keywords

Busulfan; Daunorubicin; Etoposide; Imatinib; Lymphoma; Mitoxantrone; Synergy

Indexed keywords

ADENOSINE TRIPHOSPHATE; BUSULFAN; DAUNORUBICIN; DNA; ETOPOSIDE; IMATINIB; LEUKOTHERA; LEUKOTOXIN; LIPOCORTIN 5; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITOXANTRONE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LEUKEMIA CELL LINE; MANTLE CELL LYMPHOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN BINDING;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BUSULFAN; CELL LINE, TUMOR; DAUNORUBICIN; DRUG INTERACTIONS; DRUG SYNERGISM; ETOPOSIDE; EXOTOXINS; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEUKOCYTES; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOXANTRONE; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 80053941484     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.017     Document Type: Article

References (31)

1. 2 integrin on the surface of human target cells. J Biol Chem 1997, 272:30463-30469.
2. Kachlany S.C., Schwartz A.B., Balashova N.V., et al. Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells. Leukemia Res 2010, 34:777-785.
3. Kachlany S.C. Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy. J Dent Res 2010, 89:561-570.
4. Diaz R., Ghofaily L.A., Patel J., et al. Characterization of leukotoxin from a clinical strain of Actinobacillus actinomycetemcomitans. Microb Pathog 2006, 40:48-55.
5. Kachlany S.C., Fine D.H., Figurski D.H. Purification of secreted leukotoxin (LtxA) from Actinobacillus actinomycetemcomitans. Protein Expr Purif 2002, 25:465-471.
6. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
7. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
8. Korostoff J., Wang J.F., Kieba I., Miller M., Shenker B.J., Lally E.T. Actinobacillus actinomycetemcomitans leukotoxin induces apoptosis in HL-60 cells. Infect Immun 1998, 66:4474-4483.
9. Yamaguchi N., Kieba I.R., Korostoff J., Howard P.S., Shenker B.J., Lally E.T. Maintenance of oxidative phosphorylation protects cells from Actinobacillus actinomycetemcomitans leukotoxin-induced apoptosis. Cell Microbiol 2001, 3:811-823.
10. Korostoff J., Yamaguchi N., Miller M., Kieba I., Lally E.T. Perturbation of mitochondrial structure and function plays a central role in Actinobacillus actinomycetemcomitans leukotoxin-induced apoptosis. Microb Pathog 2000, 29:267-278.
11. Smiley S.T., Reers M., Mottola-Hartshorn C., et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991, 88:3671-3675.
12. Reynolds C.P., Maurer B.J. Chemosensitivity 2005, Humana Press, Totowa, NJ.
13. Kaul S., Igwemezie L.N., Stewart D.J., et al. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol 1995, 13:2835-2841.
14. Nicoletto M.O., Padrini R., Galeotti F., et al. Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer. Cancer Chemother Pharmacol 2000, 45:457-462.
15. Sun Y.N., Chai Y.H., Xu Y.J., Lu H. Relationship between pharmacokinetics and efficacy and toxicity of daunorubicin in children with acute leukemia. Zhonghua er ke za zhi 2009, 47:296-300.
16. Schechter T., Finkelstein Y., Doyle J., et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:307-314.
17. Wang Y., Zhou L., Dutreix C., et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008, 65:885-892.
18. Fong K.P., Pacheco C.M., Otis L.L., et al. Actinobacillus actinomycetemcomitans leukotoxin requires lipid microdomains for target cell cytotoxicity. Cell Microbiol 2006, 8:1753-1767.
19. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998, 34:1514-1521.
20. Meresse P., Dechaux E., Monneret C., Bertounesque E. Etoposide: discovery and medicinal chemistry. Curr Med Chem 2004, 11:2443-2466.
21. Fox E.J. Mechanism of action of mitoxantrone. Neurology 2004, 63:S15-S18.
22. Binaschi M., Bigioni M., Cipollone A., et al. Anthracyclines: selected new developments. Curr Med Chem 2001, 1:113-130.
23. Osheroff N., Zechiedrich E.L., Gale K.C. Catalytic function of DNA topoisomerase II. Bioessays 1991, 13:269-273.
24. Kluza J., Marchetti P., Gallego M.A., et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004, 23:7018-7030.
25. Eliseev R.A., Gunter K.K., Gunter T.E. Bcl-2 prevents abnormal mitochondrial proliferation during etoposide-induced apoptosis. Exp Cell Res 2003, 289:275-281.
26. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm 2007, 13:8-12.
27. Nardi V., Azam M., Daley G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004, 11:35-43.
28. Bechter O.E., Eisterer W., Dirnhofer S., et al. Expression of LFA-1 identifies different prognostic subgroups in patients with advanced follicle center lymphoma (FCL). Leukemia Res 1999, 23:483-488.
29. Horst E., Radaszkiewicz T., Hooftman-den Otter A., et al. Expression of the leucocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia 1991, 5:848-853.
30. Inghirami G., Wieczorek R., Zhu B.Y., Silber R., Dalla-Favera R., Knowles D.M. Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia. Blood 1988, 72:1431-1434.
31. Stenderup, K., Rosada, C., Dam, T. N., Salerno, E., Belinka, B. A., Kachlany, S. C. 2011. Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. Journal of Investigative Dermatology. In press.